Dyne Therapeutics announced the resignations of two executives, new leadership appointments, and positive clinical data from its DELIVER trial for DYNE-251 in Duchenne muscular dystrophy, showing significant improvements in dystrophin expression and
AI Assistant
DYNE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.